Achilles Therapeutics向阿斯利康出售技术资产

2024-12-24 23:47

Achilles Therapeutics (NASDAQ:ACHL) said on Tuesday that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca (AZN).
TRACERx (TRAcking Cancer Evolution through therapy (Rx)), is a tumor evolution study to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients.
As part of the transaction, AstraZeneca will also take over as sponsor of Achilles’ Material Acquisition Platform (MAP), and receive tumor samples and data collected thus far.
AstraZeneca has agreed to pay Achilles Therapeutics $12M for the assets in total.
Completion of this transaction signals the conclusion of Achilles’ strategic review which was announced in September 2024.
Achilles now plans to undertake additional measures, including a further reduction in employee headcount and a decrease in the size of its Board of Directors.
Achilles Therapeutics (ACHL) shares were up more than 8% during Tuesday trading hours.

More on Achilles Therapeutics